Edition:
United Kingdom

Biocept Inc (BIOC.OQ)

BIOC.OQ on NASDAQ Stock Exchange Capital Market

0.28USD
23 Feb 2018
Change (% chg)

$0.01 (+3.24%)
Prev Close
$0.28
Open
$0.28
Day's High
$0.28
Day's Low
$0.27
Volume
99,892
Avg. Vol
250,578
52-wk High
$2.75
52-wk Low
$0.26

Chart for

About

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally... (more)

Overall

Beta: 3.04
Market Cap(Mil.): $39.03
Shares Outstanding(Mil.): 30.25
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.19 16.60
EPS (TTM): -- -- --
ROI: -- 13.90 10.66
ROE: -- 16.72 14.30

BRIEF-Biocept Prices $15 Million Public Offering Of 33.3 Mln Shares and Warrants

* BIOCEPT ANNOUNCES PRICING OF $15.0 MILLION PUBLIC OFFERING OF 33,333,333 SHARES OF COMMON STOCK AND WARRANTS TO PURCHASE 33,333,333 SHARES OF COMMON STOCK

26 Jan 2018

BRIEF-Biocept Offers 18.8 Mln Shares Of Common Stock

* BIOCEPT INC FILES TO SAY IT OFFERING 18.8 MILLION SHARES OF ITS COMMON STOCK AND WARRANTS TO PURCHASE SHARES OF COMMON STOCK - SEC FILING

22 Jan 2018

BRIEF-Biocept Inc Says Signed An In-Network Provider Agreement With Wellmark Inc

* BIOCEPT INC - HAS SIGNED AN IN-NETWORK PROVIDER AGREEMENT WITH WELLMARK INC Source text for Eikon: Further company coverage:

18 Dec 2017

BRIEF-Sabby Management LLC Reports A 9.20 Pct Passive Stake In Biocept

* SABBY MANAGEMENT LLC REPORTS A 9.20 PCT PASSIVE STAKE IN BIOCEPT INC AS OF DEC 5 - SEC FILING Source text: (http://bit.ly/2ACbgue) Further company coverage:

06 Dec 2017

BRIEF-Biocept announces pricing of public offering of up to 4,925,936 shares of common stock

* BIOCEPT ANNOUNCES PRICING OF PUBLIC OFFERING OF UP TO 4,925,936 SHARES OF COMMON STOCK

06 Dec 2017

BRIEF-Biocept And UC San Diego Medical Center Announce Clinical Study Collaboration To Demonstrate Utility Of Biocept's Liquid Biopsy Test In Immunotherapy

* BIOCEPT AND UC SAN DIEGO MEDICAL CENTER ANNOUNCE CLINICAL STUDY COLLABORATION TO DEMONSTRATE UTILITY OF BIOCEPT'S LIQUID BIOPSY TEST IN IMMUNOTHERAPY Source text for Eikon: Further company coverage:

28 Nov 2017

BRIEF-Biocept files for offering $10 mln of shares of co's common stock and warrants

* Biocept Inc files for offering $10 million of shares of co's common stock and warrants - SEC Filing

17 Nov 2017

BRIEF-Biocept reports Q3 loss per share $0.20

* Biocept Inc - ‍cash and cash equivalents were $5.9 million as of September 30, 2017​ Source text for Eikon: Further company coverage:

09 Nov 2017

BRIEF-Biocept and Miraca Life Sciences enter into marketing agreement

* Biocept and Miraca Life Sciences enter into marketing agreement to expand target selector testing in the United States

03 Oct 2017

Earnings vs. Estimates